Lupin Atlantis Holdings Completes Acquisition of Two Brands from Sanofi in Europe & Canada

Overview

Global pharma major Lupin Limited (Lupin) announced that its European hub entity, Lupin Atlantis Holdings SA, has completed the acquisition of two well-known brands, Aarane in Germany and Nalcrom in Canada and the Netherlands, along with the associated trademark rights, from Sanofi. 

Post Acquisition Impacts

• The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas, where the company has a leading position, with high-quality products that are innovative or unique in the market. 
• This acquisition will enhance Lupin's respiratory business in Germany, by aiding in the expansion of the newly established franchise, following the introduction of Luforbec. 

Nalcrom

• Nalcrom (sodium cromoglicate oral) belongs to a group of medicines called anti-allergics. 
• It is used to treat food allergies after adequate testing for sensitivity to specific allergens in conjunction with restricting the main allergens. 

About Aarane

Aarane (sodium cromoglicate/reproterol hydrochloride pressurized inhalation) is a chromone complex indicated in symptomatic acute treatment of sudden asthma attacks (e.g., allergic forms or those triggered by exertion, stress or infections) and targeted prevention of exercise-induced asthma or in cases of foreseeable allergen contact. 

Words from Lupin

Dr Fabrice Egros, president – corporate development, Lupin said, “This acquisition will strengthen our global position in treating patients suffering from diverse respiratory diseases and conditions, and it adds accretive assets in gastro-intestinal care that broaden our portfolio of branded products. We are committed to provide our customers and patients with the best products and services in the market segments where we are present, improving the quality of life for millions of people around the world.” 

About Lupin

• Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. 
• The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. 

About Sanofi

• Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. 
• Its team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible.